Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Asset Writedowns and Impairment (2021 - 2022)

BridgeBio Pharma's Asset Writedowns and Impairment history spans 2 years, with the latest figure at $67000.0 for Q3 2022.

  • For Q3 2022, Asset Writedowns and Impairment changed N/A year-over-year to $67000.0; the TTM value through Jun 2023 reached $67000.0, down 99.28%, while the annual FY2024 figure was $271000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment for Q3 2022 was $67000.0 at BridgeBio Pharma, down from $12.7 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $12.7 million in Q1 2022 and bottomed at -$3.3 million in Q4 2021.